Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Retinal Detachment
2015-004731-12Phase 3Terminated
- Sponsor
- University of Cologne
- Start
- Jun 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of fluorouracil and dalteparin in Proliferative Vitreoretinopathy (PVR) and rhegmatogenous retinal detachment (RRD), sponsored by University of Cologne. Primary endpoint: Incidence of PVR grade CP1 or higher within 12 weeks. Started Jun 2016; status: terminated.
02
Drugs
fluorouracildalteparin
03
Conditions
Proliferative Vitreoretinopathy (PVR)rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on 2015-004731-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004731-12.